Impact of Resting Heart Rate at 30 Days Following Transcatheter or Surgical Aortic Valve Replacement and Cardiovascular Outcomes: Insights from The PARTNER 2 Trial

Macedo, Leon G. R.; Kosmidou, Ioanna; Crowley, Aaron; Alu, Maria; Praz, Fabien; Chen, Shmuel; Nazif, Tamim; Babaliaros, Vasilis; Herrmann, Howard C.; Kapadia, Samir; Makkar, Raj; Webb, John; Thourani, Vinod H.; Leon, Martin B.; Kodali, Susheel

doi:10.6084/m9.figshare.6804626.v3

P2 Heart Rate (Macedo) Supplemental Appendix.docx (830.7 kB)

Impact of Resting Heart Rate at 30 Days Following Transcatheter or Surgical Aortic Valve Replacement and Cardiovascular Outcomes: Insights from The PARTNER 2 Trial

Version 3 2020-10-23, 20:20

Version 2 2018-07-31, 10:48

Version 1 2018-07-11, 16:07

journal contribution

posted on 2020-10-23, 20:20 authored by Leon G. R. Macedo, Ioanna Kosmidou, Aaron Crowley, Maria Alu, Fabien Praz, Shmuel Chen, Tamim Nazif, Vasilis Babaliaros, Howard C. Herrmann, Samir Kapadia, Raj Makkar, John Webb, Vinod H. Thourani, Martin B. Leon, Susheel Kodali

Background: Elevated resting heart rate (RHR) is associated with adverse cardiovascular outcomes in patients with untreated aortic valve stenosis (AS). However, the impact of RHR following transcatheter (TAVR) or surgical aortic valve replacement (SAVR) on cardiovascular outcomes is unknown. We therefore sought to determine the effect of RHR at 30 days after aortic valve replacement (AVR) on 2-year outcomes in patients with severe symptomatic AS.

Methods: The study population consists of 3170 patients from the PARTNER 2 Trial and its embedded registries who underwent TAVR or SAVR for severe AS, and had available 12-lead electrocardiograms demonstrating sinus rhythm at 30 days post-procedure. Outcomes at 2 years were analyzed according to 30-day RHR modeled as a continuous variable and in groups (RHR ≥75 bpm and RHR <75 bpm).

Results: By multivariable analysis, RHR ≥75 bpm at 30 days after AVR was an independent predictor of the composite endpoint of all-cause death, rehospitalization or stroke (hazard ratio [HR] 1.26, 95% confidence interval [CI], 1.05–1.52, p = 0.015) and rehospitalization (HR 1.42, 95% CI, 1.12–1.79, p = 0.004). Similarly, RHR modeled as a continuous variable (per 5 bpm) remained an independent predictor of all-cause death, rehospitalization or stroke (adjusted HR 1.07, 95% CI, 1.03–1.11, p = 0.0007), and rehospitalization (adjusted HR 1.09, 95% CI, 1.04–1.14, p = 0.0003) at 2 years.

Conclusions: In patients with severe AS treated with TAVR or SAVR, resting heart rate at 30 days post-procedure was an independent predictor of the composite endpoint of all-cause death, rehospitalization or any stroke, and of rehospitalization at 2 years.